25-Hydroxyvitamin D3 (calcifediol) therapy of juvenile renal osteodystrophy: Beneficial effect on linear growth velocity

Craig B. Langman*, Alice T. Mazur, Roland Baron, Michael E. Norman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

40 Scopus citations

Abstract

A prospective study of renal osteodystrophy in moderate renal insufficiency was undertaken to assess the effects of 25(OH)D3 (calcifediol) on healing of bone lesions and improvement of linear growth. One year after entering the study, the mean group growth velocity increased into the normal range and remained there in the next two therapy years. A significant correlation existed between pretherapy and one-year therapy values of growth velocity and serum 25(OH)D3 concentration. Qualitative bone histology obtained by transilial bone biopsy was also evaluated during the course of study. Catch-up growth was not seen, but potential for such growth may exist in later years in our patients.

Original languageEnglish (US)
Pages (from-to)815-820
Number of pages6
JournalThe Journal of pediatrics
Volume100
Issue number5
DOIs
StatePublished - May 1982

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint

Dive into the research topics of '25-Hydroxyvitamin D<sub>3</sub> (calcifediol) therapy of juvenile renal osteodystrophy: Beneficial effect on linear growth velocity'. Together they form a unique fingerprint.

Cite this